Creutzfeldt-Jakob disease (CJD) is a rapidly progressive, neurodegenerative disorder causing dramatic neuromuscular symptoms, profound dementia, and death. In this article, the epidemiology, etiology, modes of transmission, clinical manifestations, determination of possible/ probable CJD diagnosis in life, and the postmortem neuropathology of definite CJD are discussed in depth. Case studies of two individuals, each affected by different subtypes of sporadic Creutzfeldt-Jakob disease (sCJD), are presented, along with a discussion of the many challenging nursing and psychosocial issues surrounding the supportive care of these individuals and families in life and death.
Lantos PL: From slow virus to prion: A review of transmissible spongiform encephalopathies. Histopathology. 1992; 20(1): 1-11.
2.
Richardson EP, Masters CL: The nosology of Creutzfeldt-Jakob disease and conditions related to the accumulation of PrPCJD in the nervous system. Brain Pathol. 1995; 5(1): 33-41.
3.
Ghetti B, Gambetti P: Human prion diseases. In Advances in Cell Aging and Gerontology. Stamford, CT: JAI Press, 1999, 135-187.
4.
Gajdusek DC, Zigas V: Degenerative disease of the central nervous system in New Guinea. The endemic occurrence of “kuru” in the native population. N Engl J Med.1957; 257: 874-978.
5.
Johnson RT, Gibbs CJ: Creutzfeldt-Jakob disease and related transmissable spongiform encephalopathies. N Engl J Med.1998; 339: 1994-2004.
6.
Collins S, Boyd A, Fletcher A, et al.: Novel prion protein gene mutation in an octogenarian with Creutzfeldt-Jakob disease. Arch Neurol. 2000; 57(7): 1058-1063.
7.
Masters CL, Harris JO, Gajdusek D.C, et al.: Creutzfeldt-Jakob disease: Patterns of world-wide occurrence and significance of familial and sporadic clustering. Ann Neurol. 1979; 5(2): 177-187.
8.
Weber T, Aguzzi A: (1997). The spectrum of transmissible spongiform encephalopathies. Intervirology. 1997; 40(2-3): 198-212.
9.
Aguzzi A, Heppner FL: Pathogenesis of prion diseases: A progress report. Cell Death Differ.2000; 7(10): 889-902.
10.
Prusiner S: The prion diseases. Sci Am. 1995; 272(1): 48-57.
11.
Hsiao K, Baker HF, Crow TJ, et al.: Linkage of a prion protein missense variant to Gertsmann-Sträussler syndrome. Nature. 1989; 338(6213) 342-345.
12.
Brown P, Preece M, Brandel JP, et al.: Iatrogenic Creutzfeldt-Jakob disease at the millenium. Neurology. 2000; 55(8): 1075-1081.
13.
Huillard d’Aignaux H, Costagliola D, Maccario J, et al.: Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology. 1999; 53(6): 1197-1201.
14.
Chapman J, Korczyn A: Genetic and environmental factors determining the development of Creutzfeldt-Jakob disease in Libyan Jews. Neuroepidemiology. 1991; 10(5-6): 228-231.
15.
Hsiao K, Meiner Z, Kahana E, et al.: Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med.1991; 324(16): 1091-1097.
16.
Will RG, Ironside JW, Zeidler M, et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996; 347(9006): 921-925.
17.
Centers for Disease Control, National Center for Infectious Diseases: Update: 2002. Bovine Spongiform Encephalopathy and Variant Creutzfeldt-Jakob Disease. Available at: http://www.cdc.gov/ncidod/diseases/cjd/bse_cjd.htm (accessed November 25, 2002).
18.
Centers for Disease Control: Probable variant Creutzfeldt-Jakob disease in a U.S. resident-Florida, 2002. Morbidity and Mortality Weekly Report. 2002; 51(41): 927-929. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5141a3.htm (accessed, November 25, 2002).
19.
Connolly JH, Allen IV, Dermott E: Transmissible agent in amyotrophic form of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 1988; 51(11): 1459-1460.
20.
Bailey B, Aranda S, Quinn K, et al.: Clinical practice: Creutzfeldt-Jakob disease: Extending palliative care nursing knowledge. Int J Palliat Nurs. 2000; 6(3): 131-139.
21.
Chipps E, Paulson G: Creutzfeldt-Jakob disease: A review. J Neurosci Nurs. 1994; 26(4): 219-223.
Steinhoff BJ, Räcker S, Herrendorf G, et al.: Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob. Arch Neurol. 1996; 53(2): 162-166.
25.
Hansen HC, Zschocke S, Sturenburg HJ, et al.: Clinical changes and EEG patterns preceding the onset of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Acta Neurol Scand. 1998; 97(2): 99-106.
26.
Zeidler M, Steward GE, Barraclough CR, et al.: New variant Creutzfeldt-Jakob disease: Neurological features and diagnostic tests. Lancet. 1997; 350(9094): 903-907.
27.
Macleod MA, Stewart GE, Zeidler M, et al.: Sensory features of variant Creutzfeldt-Jakob disease. J Neurol. 2002; 249(6): 706-711.
28.
Spencer MD, Knight RSG,.Will RG: First hundred cases of variant Creutzfeldt-jakob disease: Retrospective case note review of early psychiatric and neurological features. Br Med J.2002; 324(7352): 1479-1482.
29.
Budka H, Aguzzi A, Brown P, et al.: Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (Prion diseases). Brain Pathol. 1995; 5(4): 459-466.
30.
Public health issues and clinical and neurological characteristics of the new variant of Creutzfeldt-Jakob disease and other human and animal transmissible spongiform encephalopathies: Memorandum from two WHO meetings (1996). Bull World Health Org.1996; 74(5): 453-463.
31.
Otto A, Zerr I, Lantsch M, et al.: Akinetic mutism as a classification criterion for the diagnosis of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 1998; 64(4): 524-528.
32.
Castellani R, Parchi P, Stahl J, et al.: Early pathologic and biochemical changes in Creutzfeldt-Jakob disease: Study of brain biopies. Neurology. 1996; 46(6): 1690-1693.
33.
Kretzschmar HA, Ironside JW, DeArmond SJ, et al.: Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol. 1996; 53(9): 913-920.
34.
Lemstra AW, van Meegen MT, Vreyling JP, et al.: 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients. Neurology. 2000; 55(4): 514-516.
35.
Zerr I, Bodemer M, Gefeller O, et al.: Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutfeldt-Jakob disease. Ann Neurol. 1998; 43(1): 32-40.
36.
Mayeux R, Foster NL, Rossor M, et al.: The clinical evaluation of patients with dementia. In Whitehouse PJ (ed.), Dementia. Philadelphia, PA: F.A. Davis Company, 1993, 92-129.
37.
Lai EC: Prion diseases. In Samuels MA, Feske S (eds.), Office Practice of Neurology. New York: Churchill Livingston, Inc., 1996, 443-444.
38.
Collie DA, Sellar RJ, Zeidler M, et al.: MRI of Creutzfeldt-Jakob disease: Imaging features and recommended MRI protocol. Clin Radiol. 2001; 56(9): 726-739.
39.
Coulthard A, Hall K, English PT, et al.: Quantitative analysis of MRI signal intensity in new variant Creutzfeldt-Jakob disease. Br J Radiol. 1999; 72(860): 742-748.
40.
Henkel K, Zerr I., Hertel A, et al.: Positron emission tomography with [(18)F] in the diagnosis of Creutzfeldt-Jakob disease. Journal of Neurology. 2002; 249(6): 699-705.
41.
Kim HC, Chang KH, Song IC, et al.: Diffusion-weighted MR imaging in biopsy-proven Creutzfeldt-Jakob disease. Korean J Radiol. 2001; 2(4): 192-196.
42.
Murata T, Shiga Y, Higano S, et al.: Conspicuity and evolution of lesions in Creutzfeldt-Jakob disease at diffusion-weighted imaging. Am J Neuroradiol. 2002; 23(7): 1164-1172.
43.
Tribl GG, Strasser G, Zeitlhofer J, et al.: Sequential MRI in a case of Creutzfeldt-Jakob disease. Neuroradiology. 2002; 44(3): 223-226.
44.
Zeidler M, Sellar RJ, Collie DA, et al.: The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet. 2000; 355(9213): 1412-1418.
45.
Ghetti B: Personal communication. July 17, 2000.
46.
National Prion Disease Pathology Surveillance Center. Available at: http://www.cjdsurveillance.com/prion.html (accessed November 18, 2002).
47.
Rotkoff N, Labosky S, Dobson J, et al.: Nursing care of the resident with Creutzfeldt-Jakob disease. Geriatr Nurs.1997; 18(4): 155-159.
48.
Burgener SC: Quality of life in late-stage dementia. In Volicer L, Hurley A (eds.): Hospice Care for Patients with Advanced Progressive Dementia. New York, NY: Springer Publishing Company, 1998, 88-113.
49.
Price DM: (Hard decisions in hard times: Making ethical choices during prolonged illness. In Doka KJ, Davidson J (eds.), Living with Grief when Illness Is Prolonged. Washington, DC: Hospice Foundation of America, 1997, 51-65.
50.
Rutala WA, Weber DJ: Creutzfeldt-Jakob disease: Recommendations for disinfection and sterilization. Clin Infect Dis.2001; 32(9): 1348-1356.
World Health Organization: WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies. Geneva, Switzerland: Report of a WHO Consultation, 1999. Available at http://www.who/cds/csr/aph/2000.3 (accessed November 11, 2002).
53.
U.S. Department of Health and Human Services, Food and Drug Administration: Center for Biologics Evaluation and Research (CBER). Guidance for Industry, Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Available at: http://www.fda.gov/cber/gdlns/cjdvcjd0602.htm (accessed November 18, 2002).
